What is PDS Biotechnology Corporation's earnings per share (EPS)?

PDS Biotechnology Corporation (PDSB) reported diluted earnings per share of -$0.74 for fiscal year 2025. This represents a 28.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

PDS Biotechnology Corporation (PDSB) Financials

PDSB

FY2025 annual

Net Income -$34.5M +8.3% YoY

EPS (Diluted) -$0.74 +28.2% YoY

Free Cash Flow -$27.8M +20.8% YoY

Operating Cash Flow -$27.8M +20.8% YoY

Market Cap $54.2M as of Oct 3, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PDSB SEC filings page.

This page shows PDS Biotechnology Corporation (PDSB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PDSB FY2025 2026-10-03

The reported business is research-led: losses are narrowing, but financing—not operations—has funded cash needs as equity thins.

Operating loss narrowed to $31.5M in FY2025 from $36.3M in FY2024. R&D also fell to $19.0M from $22.6M; because revenue is not reported, the improvement is better read as reduced spending than as proof of scale-driven operating leverage.

Total assets fell to $30.5M in FY2025, while liabilities were still $21.2M. That combination left equity at $9.3M and debt-to-equity at 2.3x, making the balance sheet increasingly dependent on external financing.

FY2025 financing supplied $12.8M against operating cash outflow of $27.8M, so capital raised did not fully offset the year's cash use. The reported liquidity comparison was 11.6 months of the latest annual outflow; that describes the period-end balance against one reported year, not a forecast.

Financial Health Signals

Financial health score not available

PDS Biotechnology Corporation does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

PDS Biotechnology Corporation passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

PDS Biotechnology Corporation reported a net loss of $34.5M while operations used $27.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

PDS Biotechnology Corporation reported an operating loss of $31.5M against $5.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$6.5M

YoY+14.8%

QoQ+0.4%

PDS Biotechnology Corporation's EBITDA was -$6.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 14.8% from the same quarter a year earlier. Against the prior quarter it is up 0.4%.

Net Income

-$9.8M

YoY-3.4%

QoQ-32.7%

PDS Biotechnology Corporation reported -$9.8M in net income in Q2 2026. This represents a decrease of 3.4% from the same quarter a year earlier. Against the prior quarter it is down 32.7%.

EPS (Diluted)

-$0.18

YoY+14.3%

QoQ-38.5%

PDS Biotechnology Corporation earned -$0.18 per diluted share (EPS) in Q2 2026. This represents an increase of 14.3% from the same quarter a year earlier. Against the prior quarter it is down 38.5%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Cash & Debt

$5.6M

YoY-82.4%

QoQ-74.2%

5Y CAGR-40.5%

10Y CAGR-25.8%

PDS Biotechnology Corporation held $5.6M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

56M

YoY+20.0%

QoQ+0.3%

5Y CAGR+14.5%

10Y CAGR+6.8%

PDS Biotechnology Corporation had 56M shares outstanding in Q2 2026. This represents an increase of 20.0% from the same quarter a year earlier. Against the prior quarter it is up 0.3%.

Free Cash Flow

Not reported for Q2 2026.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

None of these metrics is reported for Q2 2026.

Capital Allocation

R&D Spending

$3.3M

YoY-22.5%

QoQ-5.5%

PDS Biotechnology Corporation invested $3.3M in research and development in Q2 2026. This represents a decrease of 22.5% from the same quarter a year earlier. Against the prior quarter it is down 5.5%.

Share Buybacks

Not reported for Q2 2026.

Capital Expenditures

Not reported for Q2 2026.

PDSB Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PDSB quarterly income statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
R&D Expenses	N/A	$19.0M-15.7%	$22.6M-18.7%	$27.8M-5.7%	$29.4M+161.5%	$11.3M+42.0%	$7.9M+29.9%	$6.1M	N/A	$34.3M+38.2%	$24.8M+39.2%	$17.8M+110.5%	$8.5M+89.0%	$4.5M
SG&A Expenses	N/A	$12.5M-9.0%	$13.8M-10.0%	$15.3M+24.8%	$12.2M+20.2%	$10.2M+46.0%	$7.0M-36.5%	$11.0M	N/A	$17.7M+20.2%	$14.7M+69.6%	$8.7M+83.4%	$4.7M+135.6%	$2.0M
Operating Income	N/A	-$31.5M+13.2%	-$36.3M+15.6%	-$43.0M-3.3%	-$41.7M-94.4%	-$21.4M-43.9%	-$14.9M+29.2%	-$21.0M	N/A	-$52.0M-31.5%	-$39.5M-49.1%	-$26.5M-100.8%	-$13.2M-103.4%	-$6.5M
EBITDA	N/A	-$31.5M+13.2%	-$36.3M+15.6%	-$43.0M-3.3%	-$41.6M-94.2%	-$21.4M-44.0%	-$14.9M+28.9%	-$20.9M	N/A	-$51.8M-31.4%	-$39.4M-49.0%	-$26.4M-100.9%	-$13.2M-103.0%	-$6.5M
Interest Expense	N/A	$5.3M+14.6%	$4.7M+10.8%	$4.2M+219.5%	$1.3M	$0	$0-100.0%	$34K+833.5%	$4K-99.8%	$2.2M+81.1%	$1.2M+47.4%	$816K+345.7%	$183K+5361.5%	$3K
Income Tax	N/A	-$1.2M-34.6%	-$869K+38.2%	-$1.4M-17.3%	-$1.2M+73.5%	-$4.5M	$0+100.0%	-$382K	$0+100.0%	-$2.6M-40.1%	-$1.8M-66.7%	-$1.1M-87.5%	-$591K-28.7%	-$459K
Net Income	-$33.7M	-$34.5M+8.3%	-$37.6M+12.4%	-$42.9M-5.1%	-$40.9M-141.5%	-$16.9M-13.9%	-$14.8M-112.1%	-$7.0M	N/A	-$50.9M-31.0%	-$38.8M-38.3%	-$28.1M-130.1%	-$12.2M-77.3%	-$6.9M
EPS (Basic)	N/A	-$0.74+28.2%	-$1.03+25.9%	-$1.39+2.8%	-$1.43-116.7%	-$0.66+25.8%	-$0.89	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.64	-$0.74+28.2%	-$1.03+25.9%	-$1.39+2.8%	-$1.43-116.7%	-$0.66	-$0.89	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	46M+27.2%	36M+17.8%	31M+8.2%	29M+11.7%	26M	17M	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-K	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-K
R&D Expenses	$3.3M-22.5%	$3.5M-40.7%	N/A	$4.6M-32.7%	$4.2M-7.0%	$5.8M-13.0%	N/A	$6.8M+5.5%
SG&A Expenses	$3.2M-5.3%	$3.1M-6.4%	N/A	$3.6M+5.6%	$3.4M-18.0%	$3.3M-3.5%	N/A	$3.4M-17.1%
Operating Income	-$6.5M+14.8%	-$6.5M+28.4%	N/A	-$8.1M+20.0%	-$7.6M+12.2%	-$9.1M+9.8%	N/A	-$10.2M+3.2%
EBITDA	-$6.5M+14.8%	-$6.5M+28.4%	N/A	-$8.1M+20.1%	-$7.6M+12.2%	-$9.1M+9.8%	N/A	-$10.2M+3.3%
Interest Expense	$3.4M+57.6%	$1.0M+9.0%	N/A	$1.2M-5.0%	$2.1M+81.1%	$931K-20.8%	N/A	$1.2M+13.3%
Income Tax	$0	$0+100.0%	N/A	$0	$0+100.0%	-$1.2M	N/A	$0
Net Income	-$9.8M-3.4%	-$7.3M+13.4%	-$7.6M+4.9%	-$9.0M+16.0%	-$9.4M-13.3%	-$8.5M+19.9%	-$8.0M+27.0%	-$10.7M+1.1%
EPS (Basic)	-$0.18+14.3%	-$0.13+38.1%	-$0.14+33.3%	-$0.19+34.5%	-$0.21+8.7%	-$0.21+30.0%	-$0.21+40.0%	-$0.29+17.1%
EPS (Diluted)	-$0.18+14.3%	-$0.13+38.1%	-$0.14+33.3%	-$0.19+34.5%	-$0.21+8.7%	-$0.21+30.0%	-$0.21+40.0%	-$0.29+17.1%
Diluted Shares (Avg)	56M+21.3%	55M+37.0%	N/A	47M+27.3%	46M+25.1%	41M+16.4%	N/A	37M+19.1%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.

PDSB Balance Sheet

PDSB quarterly balance sheet

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Total Assets	$30.5M-32.8%	$45.4M-23.6%	$59.4M-22.9%	$77.0M+14.6%	$67.2M+117.5%	$30.9M+113.2%	$14.5M+8713.0%	$164K-99.8%	$92.6M-16.5%	$110.9M-17.3%	$134.1M+696.0%	$16.8M	N/A
Current Assets	$28.3M-37.3%	$45.1M-23.7%	$59.1M-22.8%	$76.5M+14.4%	$66.8M+120.3%	$30.3M+109.7%	$14.5M+11748.9%	$122K-99.9%	$89.1M-17.0%	$107.4M-18.2%	$131.3M+755.3%	$15.3M	N/A
Cash & Equivalents	$26.7M-35.9%	$41.7M-26.3%	$56.6M-23.4%	$73.8M+13.1%	$65.2M+126.2%	$28.8M+137.1%	$12.2M+11628.4%	$104K-99.9%	$88.1M-17.2%	$106.4M-18.3%	$130.2M+848.3%	$13.7M+74.7%	$7.9M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$21.2M-19.4%	$26.4M-20.8%	$33.3M+0.8%	$33.0M+727.7%	$4.0M+6.0%	$3.8M+34.6%	$2.8M+25.2%	$2.2M-97.6%	$93.2M+330.9%	$21.6M+86.3%	$11.6M-74.0%	$44.7M	N/A
Current Liabilities	$9.5M-44.5%	$17.1M+25.4%	$13.6M+38.8%	$9.8M+161.5%	$3.8M+14.8%	$3.3M+17.1%	$2.8M+46.3%	$1.9M-85.2%	$12.9M+92.5%	$6.7M-22.2%	$8.6M+120.6%	$3.9M	N/A
Non-Current Liabilities	$11.8M+26.9%	$9.3M-52.8%	$19.6M-15.3%	$23.2M+9918.1%	$231K-52.8%	$490K	$0-100.0%	$321K-99.6%	$80.4M+437.4%	$15.0M+394.2%	$3.0M-92.6%	$40.8M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$5.5M	N/A	N/A
Total Equity	$9.3M-51.3%	$19.0M-27.3%	$26.1M-40.6%	$44.0M-30.4%	$63.2M+133.0%	$27.1M+131.9%	$11.7M+666.1%	-$2.1M-239.0%	-$610K-100.7%	$89.3M-27.1%	$122.5M+540.0%	-$27.8M-81.3%	-$15.3M
Retained Earnings	-$216.6M-18.9%	-$182.1M-26.0%	-$144.5M-42.3%	-$101.6M-67.3%	-$60.7M-38.6%	-$43.8M-51.3%	-$28.9M-31.9%	-$21.9M+85.6%	-$151.9M-50.3%	-$101.1M-62.4%	-$62.3M-108.8%	-$29.8M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-K	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-K
Total Assets	$8.8M-78.2%	$24.7M-47.6%	$30.5M-32.8%	$34.7M-33.8%	$40.5M-33.1%	$47.0M-31.8%	$45.4M-23.6%	$52.5M-8.3%
Current Assets	$7.0M-79.1%	$22.9M-46.1%	$28.3M-37.3%	$27.9M-46.5%	$33.6M-44.1%	$42.5M-38.2%	$45.1M-23.7%	$52.1M-8.3%
Cash & Equivalents	$5.6M-82.4%	$21.7M-45.8%	$26.7M-35.9%	$26.2M-47.3%	$31.9M-44.8%	$40.0M-40.0%	$41.7M-26.3%	$49.8M-8.3%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$12.4M-49.5%	$20.8M-15.8%	$21.2M-19.4%	$25.3M-17.1%	$24.5M-17.1%	$24.7M-22.5%	$26.4M-20.8%	$30.4M-6.9%
Current Liabilities	$12.4M+7.3%	$10.1M-44.4%	$9.5M-44.5%	$13.3M-27.3%	$11.5M-26.4%	$18.3M+21.3%	$17.1M+25.4%	$18.3M+100.4%
Non-Current Liabilities	$9K-99.9%	$10.6M+66.0%	$11.8M+26.9%	$11.9M-1.5%	$13.0M-6.6%	$6.4M-61.8%	$9.3M-52.8%	$12.1M-48.6%
Total Equity	-$3.6M-122.4%	$3.9M-82.6%	$9.3M-51.3%	$9.5M-57.0%	$16.0M-48.4%	$22.4M-39.9%	$19.0M-27.3%	$22.0M-10.1%
Retained Earnings	-$233.7M-16.8%	-$224.0M-17.5%	-$216.6M-18.9%	-$209.0M-20.0%	-$200.0M-22.4%	-$190.6M-22.9%	-$182.1M-26.0%	-$174.2M-30.4%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

PDSB Cash Flow Statement

PDSB quarterly cash flow statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Operating Cash Flow	-$16.8M	-$27.8M+20.8%	-$35.0M-4.1%	-$33.6M-30.8%	-$25.7M-105.9%	-$12.5M+5.0%	-$13.1M+27.2%	-$18.1M	N/A	-$40.7M-26.4%	-$32.2M-48.0%	-$21.8M-123.9%	-$9.7M-20.8%	-$8.0M
Depreciation & Amortization	N/A	$61K+1.2%	$60K+4.3%	$57K+16.8%	$49K+816.1%	$5K-65.7%	$16K-84.1%	$98K+42.4%	$69K-62.2%	$183K+82.7%	$100K+88.5%	$53K+70.1%	$31K+602.7%	$4K
Stock-Based Compensation	N/A	$4.1M-40.0%	$6.8M-10.1%	$7.6M+46.5%	$5.2M+27.5%	$4.1M+842.5%	$432K-86.2%	$3.1M+262.1%	$867K-86.0%	$6.2M+16.5%	$5.3M+83.0%	$2.9M+123.4%	$1.3M+398.5%	$260K
Capital Expenditures	N/A	$0-100.0%	$29K	$0	N/A	N/A	N/A	N/A	$0-100.0%	$189K-72.5%	$687K-47.4%	$1.3M+47.5%	$885K+546.3%	$137K
Free Cash Flow	N/A	-$27.8M+20.8%	-$35.1M-4.2%	-$33.6M	N/A	N/A	N/A	N/A	N/A	-$40.9M-24.4%	-$32.9M-42.6%	-$23.1M-117.5%	-$10.6M-29.6%	-$8.2M
Investing Cash Flow	N/A	$0+100.0%	-$29K	$0	N/A	N/A	$0-100.0%	$29.4M	$0+100.0%	-$189K+72.5%	-$687K+47.4%	-$1.3M	N/A	N/A
Financing Cash Flow	-$9.5M	$12.8M-36.7%	$20.2M+23.3%	$16.4M-52.2%	$34.3M-29.9%	$48.9M+63.9%	$29.8M+3876.9%	$750K	N/A	$22.6M+148.3%	$9.1M-93.5%	$139.5M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-K	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-K
Operating Cash Flow	-$2.8M+69.3%	-$4.4M+51.6%	-$3.7M+55.0%	-$5.9M+26.0%	-$9.1M-2.7%	-$9.0M+9.1%	-$8.2M+2.6%	-$8.0M-11.5%
Depreciation & Amortization	$15K0.0%	$15K0.0%	$15K0.0%	$15K0.0%	$15K0.0%	$15K+5.0%	$15K+5.0%	$15K+5.1%
Stock-Based Compensation	$1.1M+151.3%	$1.2M-7.8%	N/A	$1.2M-29.9%	$448K-75.1%	$1.3M-23.1%	N/A	$1.8M
Capital Expenditures	N/A	N/A	$0	$0-100.0%	N/A	N/A	$0	$1
Free Cash Flow	N/A	N/A	-$3.7M+55.0%	-$5.9M+26.0%	N/A	N/A	-$8.2M+2.6%	-$8.0M-11.5%
Investing Cash Flow	N/A	N/A	$0	$0+100.0%	N/A	N/A	$0	-$1
Financing Cash Flow	-$13.3M-1432.6%	-$680K-109.3%	$4.2M+2340.1%	$241K+1301.1%	$996K+7324.3%	$7.3M-63.4%	$173K-98.4%	$17K-97.9%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

PDSB Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PDSB quarterly financial ratios

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K
Return on Equity	-372.8%-174.9pp	-197.9%-33.6pp	-164.3%-71.5pp	-92.8%-66.1pp	-26.8%+28.0pp	-54.7%+5.1pp	-59.8%	N/A	N/A	-43.5%-20.6pp	-22.9%	N/A	N/A
Return on Assets	-113.1%-30.2pp	-82.9%-10.6pp	-72.3%-19.3pp	-53.0%-27.9pp	-25.2%+22.9pp	-48.1%+0.2pp	-48.3%	N/A	-54.9%-19.9pp	-35.0%-14.1pp	-20.9%+51.5pp	-72.4%	N/A
Current Ratio	2.98+0.3x	2.64-1.7x	4.33-3.5x	7.79-10.0x	17.80+8.5x	9.28+4.1x	5.18+5.1x	0.06-6.9x	6.92-9.1x	16.06+0.8x	15.28+11.3x	3.94	N/A
Debt-to-Equity	2.30+0.9x	1.39+0.1x	1.27+0.5x	0.75+0.7x	0.06-0.1x	0.14-0.1x	0.24	N/A	N/A	0.24+0.2x	0.04	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-K	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-K
Return on Equity	N/A	-188.8%-150.8pp	-81.8%-39.9pp	-95.3%-46.5pp	-59.1%-32.2pp	-38.0%-9.4pp	-41.8%-0.1pp	-48.8%-4.4pp
Return on Assets	-110.7%-87.4pp	-29.8%-11.8pp	-24.8%-7.3pp	-26.0%-5.5pp	-23.3%-9.5pp	-18.1%-2.7pp	-17.5%+0.8pp	-20.4%-1.5pp
Current Ratio	0.57-2.3x	2.26-0.1x	2.98+0.3x	2.09-0.7x	2.92-0.9x	2.33-2.2x	2.64-1.7x	2.84-3.4x
Debt-to-Equity	N/A	5.34+4.2x	2.30+0.9x	2.67+1.3x	1.54+0.6x	1.10+0.2x	1.39+0.1x	1.380.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
PDS Biotechnology Corporation PDSB	FY2025	N/A	-$34.5M	N/A	$54.2M	—
Cue Biopharma, Inc. CUE	FY2025	$27.5M	-$26.6M	-96.9%	$185.8M	63/100
MAIA Biotechnology, Inc. MAIA	FY2025	N/A	-$22.4M	N/A	$73.5M	—
CAMP4 Therapeutics Corporation CAMP	FY2025	$3.5M	-$80.4M	N/A	$251.0M	64/100
PolyPid Ltd. PYPD	FY2025	N/A	-$34.2M	N/A	$105.4M	—
vTv Therapeutics Inc. VTVT	FY2025	$0	-$27.0M	N/A	$120.9M	—

Where PDS Biotechnology Corporation Ranks

Frequently Asked Questions

Is PDS Biotechnology Corporation profitable?

No, PDS Biotechnology Corporation (PDSB) reported a net income of -$34.5M in fiscal year 2025.

What is PDS Biotechnology Corporation's EBITDA?

PDS Biotechnology Corporation (PDSB) had EBITDA of -$31.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is PDS Biotechnology Corporation's return on equity (ROE)?

PDS Biotechnology Corporation (PDSB) has a return on equity of -372.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is PDS Biotechnology Corporation's free cash flow?

PDS Biotechnology Corporation (PDSB) recorded an outflow of $27.8M in free cash flow during fiscal year 2025. This represents a 20.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is PDS Biotechnology Corporation's operating cash flow?

PDS Biotechnology Corporation (PDSB) recorded an outflow of $27.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are PDS Biotechnology Corporation's total assets?

PDS Biotechnology Corporation (PDSB) had $30.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are PDS Biotechnology Corporation's capital expenditures?

PDS Biotechnology Corporation (PDSB) reported no capital expenditure during fiscal year 2025.

How much does PDS Biotechnology Corporation spend on research and development?

PDS Biotechnology Corporation (PDSB) invested $19.0M in research and development during fiscal year 2025.

How many shares does PDS Biotechnology Corporation have outstanding?

PDS Biotechnology Corporation (PDSB) had 56M shares outstanding as of fiscal year 2025.

What is PDS Biotechnology Corporation's current ratio?

PDS Biotechnology Corporation (PDSB) had a current ratio of 2.98 as of fiscal year 2025, which is generally considered healthy.

What is PDS Biotechnology Corporation's debt-to-equity ratio?

PDS Biotechnology Corporation (PDSB) had a debt-to-equity ratio of 2.30 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is PDS Biotechnology Corporation's return on assets (ROA)?

PDS Biotechnology Corporation (PDSB) had a return on assets of -113.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is PDS Biotechnology Corporation's P/E ratio?

PDS Biotechnology Corporation (PDSB) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $54.2M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is PDS Biotechnology Corporation's price-to-sales ratio?

PDS Biotechnology Corporation (PDSB) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $54.2M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does PDS Biotechnology Corporation's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, PDS Biotechnology Corporation (PDSB) held $26.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $27.8M over that year. Dividing the one by the other, the reported balance equals about 12 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is PDS Biotechnology Corporation's Piotroski F-Score?

PDS Biotechnology Corporation (PDSB) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are PDS Biotechnology Corporation's earnings high quality?

PDS Biotechnology Corporation (PDSB) reported a net loss of $34.5M while operations used $27.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can PDS Biotechnology Corporation cover its interest payments?

PDS Biotechnology Corporation (PDSB) reported an operating loss of $31.5M against $5.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.